Stocks Health care TARA
NASDAQ · Health careProtara Therapeutics, Inc. (TARA)
It posted a net loss of $78.4M. In fiscal 2025 capital spending exceeded operating cash flow by $56.5M. At September 30, 2026 it held $25.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Protara Therapeutics, Inc.
- Net worth
- Protara Therapeutics, Inc. has a market value (market cap) of $148.3M at the latest share price, and shareholders' equity of $141M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $56.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Protara Therapeutics, Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Protara Therapeutics, Inc. does
Protara Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TARA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$57.4M | -$1.34 | -$56.5M |
| 2024 | n/a | -$44.6M | -$2.17 | -$35.9M |
| 2023 | n/a | -$40.4M | -$3.57 | -$37.6M |
| 2022 | n/a | -$66M | -$5.86 | -$26.6M |
| 2021 | n/a | -$47.3M | -$4.21 | -$35.1M |
| 2020 | n/a | -$34M | -$4.70 | -$24.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Protara Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- November 6, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- July 7, 2026Passive stake changed SCHEDULE 13G/A
- June 29, 2026
- June 15, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Protara Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Shefferman JesseCEO and President, Director | Gave as a gift | 14,000 | - |
| June 30, 2026 | Shefferman JesseCEO and President, Director | Gave as a gift | 7,000 | - |
| June 30, 2026 | Shefferman JesseCEO and President, Director | Gave as a gift | 4,000 | - |
| June 30, 2026 | Shefferman JesseCEO and President, Director | Gave as a gift | 5,000 | - |
| June 29, 2026 | Shefferman JesseCEO and President, Director | Exercised options | 215,687 | $412K |
| June 29, 2026 | Shefferman JesseCEO and President, Director | Sold | 215,687 | $882.2K |
| June 2, 2026 | Conkling WilliamChief Commercial Officer | Shares withheld for tax | 6,008 | $26.1K |
| April 8, 2026 | Zummo JacquelineChief R&D Officer | Soldpre-planned (10b5-1) | 1,134 | $6.1K |
Who owns TARA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| JANUS HENDERSON GROUP Ltd.13G, passive | 8.4% | August 13, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 5.7% | July 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 120 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 4,696,709 | new |
| BlackRock, Inc. | 3,663,499 | +268,531 |
| Millennium Management LLC | 3,101,166 | +269,958 |
| Velan Capital Investment Management LP | 2,844,652 | +10,000 |
| Vanguard Capital Management LLC | 2,300,133 | +181,115 |
| Blackstone Inc. | 2,265,514 | 0 |
| Orbimed Advisors LLC | 2,220,000 | new |
| Sio Capital Management, LLC | 1,921,872 | -47,967 |
| Acorn Capital Advisors, LLC | 1,752,115 | 0 |
| Integral Health Asset Management, LLC | 1,500,000 | -250,000 |
| 5AM Venture Management, LLC | 1,369,782 | 0 |
| Geode Capital Management, LLC | 1,326,246 | +149,046 |
| Citadel Advisors LLC | 1,232,365 | +163,807 |
| State Street Corp | 1,068,295 | +63,153 |
| Qube Research & Technologies Ltd | 1,045,516 | +868,512 |
| Balyasny Asset Management L.P. | 1,026,691 | new |
| Baker Bros. Advisors LP | 971,614 | 0 |
| ADAR1 Capital Management, LLC | 940,512 | 0 |
| Bank of America Corp | 882,179 | -43,739 |
| Marshall Wace, Llp | 701,021 | +650,290 |
Insiders
6 insiders reported holding 1,041,670 shares in total, about $2.6M at the last price.
| Holder | Shares |
|---|---|
| Shefferman JesseCEO and President, Director | 691,832 |
| Zummo JacquelineChief R&D Officer | 94,827 |
| Nicacio Leonardo VianaChief Medical Officer | 78,181 |
| Conkling WilliamChief Commercial Officer | 69,992 |
| Fabbio PatrickChief Financial Officer | 64,115 |
| Fry HannahVP, Controller | 42,723 |
Questions about TARA
What does Protara Therapeutics, Inc. do?
Protara Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TARA. Its shares trade on NASDAQ under the ticker TARA.
What is Protara Therapeutics, Inc.'s net worth?
Protara Therapeutics, Inc. has a market value (market cap) of $148.3M at the latest share price, and shareholders' equity of $141M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Protara Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $78.4M.
When did Protara Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Protara Therapeutics, Inc.'s next earnings report?
Protara Therapeutics, Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TARA with
Follow TARA
Get an email when Protara Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Protara Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.